2018 Volume 41 Issue 10 Pages 1574-1580
Members of the hydroxycarboxylic acid receptor (HCA1–3) family are mainly expressed in adipocytes and immune cells. HCA2 ligand, niacin, has been used for decades as lipid-modifying drug. Recent studies suggest that HCA ligands can be involved in the modulation of inflammatory processes. In this study, we evaluated the effects of HCA1–3 ligands on adipose differentiation and cytokine expression in human adipocytes and macrophages. Simpson–Golabi–Behmel syndrome (SGBS) preadipocytes were induced to differentiate into adipocytes for 8 d in the presence or absence of HCA ligands and evaluated for lipid accumulation and adipogenic gene expression. The inhibitory effects of the ligands on the expression and production of cytokines were measured in lipopolysaccharide (LPS)-stimulated adipocytes and THP-1 macrophage cells. Preadipocytes treated with HCA ligands showed no changes in the capacity to differentiate into adipocytes and no significant alteration in peroxisome proliferator activated receptor γ (PPARγ) or its target gene expression. HCA2–3 ligands significantly downregulated LPS-induced expression of interleukin (IL)-6 (53–64%), tumor necrosis factor-α (TNF-α) (55–69%) and IL-8 (51–59%) in adipocytes and macrophages. IL-1β inhibition (58–68%) by HCA2–3 ligands was observed only in adipocytes. Furthermore, LPS increased the expression of HCA2–3 in adipocytes and macrophages and this expression was decreased by treatment with their ligands. These results suggest that HCA ligands modulated LPS-mediated pro-inflammatory gene expression in both macrophages and adipocytes without affecting adipogenesis. Therefore, targeting HCA2 and HCA3 would be beneficial in treating inflammation conditions associated with atherosclerosis and obesity.
